MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,290,948K
Net Income
$157,250K
Net Profit Margin
12.18%
EPS
$1.21
Unit: Thousand (K) dollars
Revenue Breakdown
Amvuttra
GIVLAARI
Royalty
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
1,290,948
1,167,175
1,097,033
1,249,026
Cost of goods sold
298,261
207,520
267,723
197,231
Cost of collaborations and royalties
190
3,602
0
2,923
Research and development
413,134
364,866
372,218
358,814
Selling, general and administrative
347,922
322,551
325,374
322,076
Total operating costs and expenses
1,059,507
898,539
965,315
881,044
Income (loss) from operations
231,441
268,636
131,718
367,982
Interest expense
82,051
69,286
129,337
44,398
Interest income
28,143
26,598
26,630
28,681
Gain related to convertible debt
-
-
3,327
39,146
Other income (expense), net
273
-4,295
135,453
-74,150
Total other expense, net
-53,635
-46,983
29,419
-129,013
Income (loss) before income taxes
177,806
221,653
161,137
238,969
Provision for income taxes
13,312
15,662
-25,282
-12,115
Net income (loss)
164,494
205,991
186,419
251,084
Unrealized (gaines) losss on marketable securities
-3,635
-3,652
-2
1,131
Foreign currency translation (gaines) losss
-3,698
-1,234
860
6,993
Defined benefit pension plans, net of tax
-89
-89
-820
-53
Total other comprehensive (gain) income
-7,244
-4,797
1,678
8,177
Comprehensive income (loss)
157,250
201,194
188,097
259,261
Basic EPS
1.23
1.55
1.422
1.91
Diluted EPS
1.21
1.51
1.333
1.84
Basic Average Shares
133,606,000
132,893,000
132,265,000
131,447,000
Diluted Average Shares
138,281,000
138,226,000
141,084,000
137,348,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
US
$809,079K
(3568.79%↑ Y/Y)
Europe
$119,010K
(460.15%↑ Y/Y)
Non USOr Europe
$83,673K
(805.65%↑ Y/Y)
US
$9,863K
(-97.27%↓ Y/Y)
Europe
$5,508K
(-94.07%↓ Y/Y)
Non USOr Europe
$3,090K
(-91.81%↓ Y/Y)
US
$58,000K
(5.17%↑ Y/Y)
Europe
$24,323K
(16.01%↑ Y/Y)
Non USOr Europe
$7,441K
(57.25%↑ Y/Y)
Europe
$22,678K
(3.42%↑ Y/Y)
US
$18,545K
(15.77%↑ Y/Y)
Non USOr Europe
$10,899K
(22.13%↑ Y/Y)
Amvuttra
$1,011,762K
(105.66%↑ Y/Y)
ONPATTRO
$18,461K
(-64.86%↓ Y/Y)
GIVLAARI
$89,764K
(11.03%↑ Y/Y)
OXLUMO
$52,122K
(11.20%↑ Y/Y)
TTR
$1,030,223K
(89.21%↑ Y/Y)
Rare
$141,886K
(11.09%↑ Y/Y)
Roche
$41,888K
(129.31%↑ Y/Y)
Regeneron
Pharmaceuticals Incorporation
$5,020K
(-84.57%↓ Y/Y)
Other Collaborations
$257K
(-97.60%↓ Y/Y)
Product
$1,172,109K
(74.37%↑ Y/Y)
Royalty
$71,674K
(79.27%↑ Y/Y)
Collaborations
$47,165K
(-23.30%↓ Y/Y)
Total revenues
$1,290,948K
(66.86%↑ Y/Y)
Income (loss) from
operations
$231,441K
(1528.74%↑ Y/Y)
Total operating costs
and expenses
$1,059,507K
(34.13%↑ Y/Y)
Income (loss) before
income taxes
$177,806K
(602.87%↑ Y/Y)
Total other expense,
net
-$53,635K
(-179.95%↓ Y/Y)
Interest income
$28,143K
(2.39%↑ Y/Y)
Other income
(expense), net
$273K
(104.27%↑ Y/Y)
Research and development
$413,134K
(27.66%↑ Y/Y)
Selling, general and
administrative
$347,922K
(7.61%↑ Y/Y)
Cost of goods sold
$298,261K
(110.00%↑ Y/Y)
Cost of
collaborations and royalties
$190K
(-79.44%↓ Y/Y)
Net income (loss)
$164,494K
(348.19%↑ Y/Y)
Provision for income taxes
$13,312K
(-56.95%↓ Y/Y)
Interest expense
$82,051K
(103.87%↑ Y/Y)
Comprehensive income (loss)
$157,250K
(367.83%↑ Y/Y)
Total other
comprehensive (gain) income
-$7,244K
(-195.76%↓ Y/Y)
Defined benefit pension
plans, net of tax
-$89K
(-67.92%↓ Y/Y)
Foreign currency
translation (gaines) losss
-$3,698K
(-147.08%↓ Y/Y)
Unrealized (gaines) losss
on marketable...
-$3,635K
(-959.77%↓ Y/Y)
Buy us a coffee
logo (21)-svg-svg
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
logo (21)-svg-svg
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
🚨
Price Alert:
The stock price dropped by 23.04% after the earning call.
Show more